



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

Date: March 6, 2009

To: Primary Clinical Research Associates

From: Sara M. Braun
Research Protocol Specialist III

Re: N0775, A Randomized Phase II Trial of Temozolomide (TMZ) and Avastin® or
ABI-007/Carboplatin (CBDCA) and Avastin® in Patients with Unresectable Stage IV Malignant
Melanoma

The attached End of Active Treatment/Cancel Notification Form has been revised as follows:

- 1=Observation added as a “go to” option

If you have any questions, please feel free to contact me.

Thank you.